Ongoing Clinical Trials
Urologic Oncology
Customized Ablation of the Prostate with the TULSA Procedure Against radIcal prostatectomy treatmeNt: a randomized controlled trial for localized prostate cancer (CAPTAIN)
Principal Investigator: Geoffrey Sonn, MD
Contact: Julia Gallagher-Teske jgteske@stanford.edu
ClinicalTrials.gov#: NCT05027477
Phase 3, Randomized Study of CG0070 versus Observation for the Treatment of Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR-NMIBC) Following Transurethral Resection of Bladder Tumor (TURBT)
Principal Investigator: Eila C. Skinner, MD, Eugene Shkolyar, MD
Contact: Kristine Talavera kriscima@stanford.edu
ClinicalTrials.gov#: NCT06111235
A Phase III Study of Cabazitaxel with or without Carboplatin in Patients with Metastatic Castrate Resistant Prostate Cancer (MCRPC), Stratified by Aggressive Variant Signature
Principal Investigator: Sandy Srinivas, MD
Contact: Sneha Mohile smohile@stanford.edu
ClinicalTrials.gov#: NCT06470243
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of Adjuvant Therapy in Urothelial Cancer
Principal Investigator: Ali Raza Khaki, MD
Contact: Sneha Mohile smohile@stanford.edu
ClinicalTrials.gov#: NCT05987241
S8192 A Phase II/III trial of Durvalumab and Chemotherapy for Patients with High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy
Principal Investigator: Ali Raza Khaki, MD
Contact: Sneha Mohile smohile@stanford.edu
ClinicalTrials.gov#: NCT04628767
Urology
A Real World Study of eCoin® for Urgency Urinary Incontinence: Post Approval Evaluation (RECIPE)
Principal Investigator: Craig Comiter, MD
Contact: Julia Gallagher-Teske jgteske@stanford.edu
ClinicalTrials.gov#: NCT05685433
Double-s: A Wearable for Erectile Dysfunction
Principal Investigator: Michael Eisenberg, MD
Contact: Satvir Basran sbasran@stanford.edu
ClinicalTrials.gov#: NCT05451563
Prostate stimulation for sexual dysfunction
Principal Investigator: Michael Eisenberg, MD
Contact: Satvir Basran sbasran@stanford.edu
ClinicalTrials.gov#: NCT05468931
A Study to Learn How Effective and Safe the Drug 'Mirabegron' is and How Long it Stays in the Body of Children Aged 6 Months to Less Than 3 Years of Age With Neurogenic Detrusor Overactivity
Principal Investigator: William Kennedy, MD
Contact: Rachelle Balili rbalili@stanford.edu
ClinicalTrials.gov#: NCT05621616
Meet Our Team
Satvir Basran
Clinical Research Coordinator
Email: sbasran@stanford.edu
Rachelle Balili
Clinical Research Coordinator (Peds)
Email: rbalili@stanford.edu
Julia Gallagher-Teske
Clinical Research Coordinator
Email: jgteske@stanford.edu
Vinh la
Clinical Research Coordinator
Email: vinhla96@stanford.edu
Sneha Mohile
Clinical Research Coordinator
Email: smohile@stanford.edu
Sophia Prendiville
Clinical Research Coordinator
Email: prend19@stanford.edu
Ned Realiza
Clinical Research Manager
Email: nrealiza@stanford.edu
Gabriela (Gaby) Rodriguez
Clinical Research Coordinator
Email: grod094@stanford.edu
Kristine Talavera
Clinical Research Coordinator
Email: kriscima@stanford.edu
Meredith West
Clinical Research Coordinator/ Data Analyst
Email: mwest2@stanford.edu
From left to right: Rachelle Balili, Satvir Basran, Sophia Prendiville, Gaby Rodriguez, Julia Gallagher-Teske, Kristine Talavera, Ned Realiza, Sneha Mohile.